The science behind the weight-loss drug everyone is talking about — and why exercise and nutrition still matter more than ever.

 

GLP-1 receptor agonists — the class of medications behind Ozempic and Wegovy — have become one of the most talked-about developments in metabolic health in decades. As a sports nutritionist, I’m asked about them constantly.

Here’s a clear look at what the evidence actually says, who these drugs were designed for, and what happens when you stop taking them.

What is GLP-1, exactly?

GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after eating. It does two important things: it signals your brain to reduce appetite, and it prompts the pancreas to release insulin in response to rising blood sugar. GLP-1 receptor agonist (GLP-1RA) medications are synthetic versions of this hormone that work on the same receptors in the body.[1]

The result is a meaningful reduction in hunger, slower gastric emptying, and faster feelings of fullness. Blood sugar improves. Weight drops — often with less conscious effort than traditional calorie restriction.

Who are these drugs actually for?

This is the part that often gets lost in social media coverage: GLP-1RA medications were developed to treat Type 2 diabetes and obesity — both chronic diseases.

Weight loss was an unintentional side effect that became clinically significant.[1]

These drugs are designed to be chronic disease management tools, comparable to blood pressure or cholesterol medication. They are meant to be taken long-term, not as a finite course of treatment.

That said, semaglutide (Ozempic and Wegovy) were the second-best selling drug in 2024. [7]

Important: The FDA has not established a safe risk-to-benefit ratio for people who do not have obesity. These medications have not been sufficiently studied in non-obese populations.[1]

What happens when you stop?

This is the most clinically important question — and the evidence is unambiguous. Weight regain after stopping GLP-1RA medication is significant and well-documented across multiple independent meta-analyses.

A 2025 systematic review and meta-analysis by Tzang et al. (18 RCTs, 3,771 participants) found that stopping GLP-1RA therapy in adults with obesity results in a mean weight gain of 5.63 kg, alongside increases in HbA1c, waist circumference, and blood pressure — a broad reversal of cardiometabolic benefits.[2]

A separate 2026 systematic review and nonlinear meta-regression by Budini et al. (University of Cambridge, 48 studies) modelled the trajectory of regain over time. At one year post-cessation, 60% of lost weight had been regained. Their model projects weight regain to plateau at approximately 75.6% of the weight lost during treatment — meaning most, but not all, of the benefit is eventually lost.[3]

Notably, the authors caution that it remains unknown whether the regained weight is fat, muscle, or both — a critical gap for active populations.

The yo-yo dieting parallel 

What makes stopping GLP-1 medications particularly concerning from a metabolic standpoint is how the weight comes back. The hormonal cascade that follows discontinuation closely mirrors what we already know about traditional yo-yo dieting:

• Ghrelin (the hunger hormone) rises
• Leptin (the satiety hormone) and peptide YY fall
• Metabolic rate drops

These hormonal changes can persist for at least a year after stopping the medication.[2,3] Critically, emerging evidence suggests the body tends to regain fat disproportionately relative to lean tissue — raising the risk of adverse body composition shifts compared to someone who never started treatment.[3,4] 

GLP-1s do not fix the root cause

This is the point I most want my clients to understand: GLP-1 medications reduce the symptoms of a metabolic problem without addressing what caused that problem in the first place. They do not address the behavioral and environmental drivers of weight gain like: 

• • Nutrition habits
  • Exercise or movement routine
  • Sleep quality
  • Insulin resistance
  • Hormonal balance
  • Chronic stress or cortisol dysregulation

We live in an obesogenic environment — one that makes weight gain easy and healthy movement and eating genuinely difficult. When the medication stops, those underlying drivers are still present. And the metabolic environment that contributed to weight gain in the first place is still intact.

What about risks for active people without obesity?

For athletes or active individuals using GLP-1s primarily as a weight-loss shortcut, the risk profile changes significantly. Without the protective context of obesity or Type 2 diabetes, the risk-to-benefit calculation is unclear — and the FDA has not established that it is safe for this population.[1]

Known risks without medical supervision include acute pancreatitis, dehydration, nutritional deficiencies, and — especially relevant for athletes — long term muscle and bone loss.

Safety issues such as gastrointestinal side effects, pancreatitis, gallbladder disease, thyroid cancer, and psychiatric risks remain under investigation, warranting cautious patient selection and monitoring. [8]

The 2025 Kolli et al. meta-analysis found that semaglutide showed the highest absolute weight regain after discontinuation, with a mean difference of about 5.15 kg regained.[5]

The good news: lifestyle changes amplify and preserve results

Research shows that individuals who paired GLP-1 medication use with improved nutrition and regular exercise were better able to preserve some fat loss after discontinuing — and retained more lean mass throughout treatment.[6]

Even modest weight reduction has meaningful metabolic benefits. A 3–7% reduction in body weight — for example, 5–10 lbs on a 150 lb person — is associated with improvements in insulin sensitivity, blood pressure, and lipids. This is achievable through lifestyle intervention alone for many people, without the associated risks of medication.

 

The bottom line

GLP-1 medications are a legitimate, evidence-based tool for managing chronic metabolic disease. For people with obesity or Type 2 diabetes, the evidence for long-term cardiovascular, renal, and metabolic benefits is compelling — provided the medication is taken continuously and under medical supervision.

But they are not meant to be used as a finite course of treatment. They are not a substitute for lifestyle changes like improving nutrition and exercise, and not without meaningful risk when used outside their intended population. 

The evidence strongly suggests that optimizing your nutrition, exercise, sleep, hormonal health, and stress management remains the foundation of long-term metabolic health — with or without medication.

References:

1. Ward, L. (Host). (2026, February 21). Q&A: “GLP-1 Supplements” vs Ozempic: What They Can (and Can’t) Do, Plus 9 Nutrition Questions Answered [Audio podcast episode]. No. 154. Leanne Ward Nutrition.
2. Tzang C-C, Wu P-H, Luo C-A, Chen Z-T, Lee Y-T, Huang ES, Kang Y-F, Lin W-C, Tzang B-S, Hsu T-C. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine. 2025 Nov 28;90:103680. doi: 10.1016/j.eclinm.2025.103680. PMID: 41399474.
3. Budini B, Luo S, Tam M, et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine. 2026;93. doi: 10.1016/j.eclinm.2026.XXXX. [Note: the ~75% plateau figure is a modelled projection beyond 52 weeks, not a directly measured 1-year outcome.]
4. Jiang N, Yin J, Lawrence N, et al. Repeated withdrawal of a GLPR agonist induces hyperleptinemia and deteriorates metabolic health in obese aging UM-HET3 mice. Aging Cell. 2025 Oct;24(10):e70210. doi: 10.1111/acel.70210. PMID: 40960340. [Preclinical mouse model — human cycling data remain limited.]
5. Kolli RT, Aoutla S, Jyothi N, et al. Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of GLP-1 Receptor Agonists and Other Anti-obesity Drugs. Cureus. 2025 Oct 19;17(10):e94926. doi: 10.7759/cureus.94926. PMID: 41116804.
6. Codella R, Senesi P, Luzi L. GLP-1 agonists and exercise: the future of lifestyle prioritization. Front Clin Diabetes Healthc. 2025 Nov 24;6:1720794. doi: 10.3389/fcdhc.2025.1720794. PMID: 41367404; PMCID: PMC12683586.
7. Verdin P. Top companies and drugs by sales in 2024. Nat Rev Drug Discov. 2025. 10.1038/d41573-025-00049-3. 
8. Cedirian S, Donati M, Rapparini L, Pampaloni F, La Placa M, Sgarzani R, Negosanti L, Raschi E, Starace M. Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons. Dermatol Ther (Heidelb). 2025 Nov;15(11):3173-3193. doi: 10.1007/s13555-025-01537-5. Epub 2025 Sep 9. PMID: 40924351; PMCID: PMC12549488.

 

Want personalized guidance on metabolic health, body composition, and performance nutrition?

Book a consult